The global Bio-Therapeutic Glycoproteins market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Bio-Therapeutic Glycoproteins are bioactive compounds with carbohydrates attached to proteins. Glycan is the specific site where carbohydrate attaches to proteins and process of production is called glycosylation. Bio-therapeutic glycoproteins produced with glycan moieties that are similar to natural mammal glycans. The most common types are glycosylation O-linked and N-linked that are mainly depends on protein sequence attachment. Carbohydrates linked to proteins through either 伪 and 尾 linkages. Glycosylation is an important process of bio-therapeutic glycoproteins because it is critically modulated into bioactivity, stability, solubility against proteolysis, yield, clearance rate from circulation and immunogenicity. The bio-therapeutic glycoproteins mainly produced by yeast expression systems, insect cells, mammalian systems, and plant-based expression systems. In yeast expression systems, yeast is cultured chemically to scale up fermentation to an industrial level. Yeast and human share same N-glycan's linkage. Insect cells represent an alternative system for expression of recombinant bio-therapeutic proteins. Later recombinant proteins are separated from insect cells. Mammalian Systems are used to produce complex bio-therapeutic glycoproteins. Most of the FDA approved bio-therapeutic glycoproteins derived from mammalian systems. Plant-based expression systems used for the scale-up production of glycoproteins. Among all systems, mammalian systems are well established in pharmaceuticals. Some examples of bio-therapeutic glycoproteins include tocilizumab, bevacizumab, adalimumab, etc.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report includes an overview of the development of the Bio-Therapeutic Glycoproteins industry chain, the market status of Oncology and Haematology (Antisera, Cytokines), Diabetes (Antisera, Cytokines), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Bio-Therapeutic Glycoproteins.
Regionally, the report analyzes the Bio-Therapeutic Glycoproteins markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Bio-Therapeutic Glycoproteins market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Bio-Therapeutic Glycoproteins market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Bio-Therapeutic Glycoproteins industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Antisera, Cytokines).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Bio-Therapeutic Glycoproteins market.
Regional Analysis: The report involves examining the Bio-Therapeutic Glycoproteins market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Bio-Therapeutic Glycoproteins market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Bio-Therapeutic Glycoproteins:
Company Analysis: Report covers individual Bio-Therapeutic Glycoproteins manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Bio-Therapeutic Glycoproteins This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology and Haematology, Diabetes).
Technology Analysis: Report covers specific technologies relevant to Bio-Therapeutic Glycoproteins. It assesses the current state, advancements, and potential future developments in Bio-Therapeutic Glycoproteins areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Bio-Therapeutic Glycoproteins market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Bio-Therapeutic Glycoproteins market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Antisera
Cytokines
Clotting Factors
Hormones
Enzymes
Enzyme Inhibitors
Market segment by Application
Oncology and Haematology
Diabetes
Cardiology
Inflammatory Diseases
Others
Major players covered
Genentech
Hoffmann-La Roche
Genzyme Corp
Abbott Laboratories
Amgen
Biogen
Merck
GlaxoSmithKline
Novartis Pharmaceuticals Corp
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bio-Therapeutic Glycoproteins product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bio-Therapeutic Glycoproteins, with price, sales, revenue and global market share of Bio-Therapeutic Glycoproteins from 2019 to 2024.
Chapter 3, the Bio-Therapeutic Glycoproteins competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bio-Therapeutic Glycoproteins breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Bio-Therapeutic Glycoproteins market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bio-Therapeutic Glycoproteins.
Chapter 14 and 15, to describe Bio-Therapeutic Glycoproteins sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope of Bio-Therapeutic Glycoproteins
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Bio-Therapeutic Glycoproteins Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Antisera
1.3.3 Cytokines
1.3.4 Clotting Factors
1.3.5 Hormones
1.3.6 Enzymes
1.3.7 Enzyme Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global Bio-Therapeutic Glycoproteins Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oncology and Haematology
1.4.3 Diabetes
1.4.4 Cardiology
1.4.5 Inflammatory Diseases
1.4.6 Others
1.5 Global Bio-Therapeutic Glycoproteins Market Size & Forecast
1.5.1 Global Bio-Therapeutic Glycoproteins Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Bio-Therapeutic Glycoproteins Sales Quantity (2019-2030)
1.5.3 Global Bio-Therapeutic Glycoproteins Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Genentech
2.1.1 Genentech Details
2.1.2 Genentech Major Business
2.1.3 Genentech Bio-Therapeutic Glycoproteins Product and Services
2.1.4 Genentech Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Genentech Recent Developments/Updates
2.2 Hoffmann-La Roche
2.2.1 Hoffmann-La Roche Details
2.2.2 Hoffmann-La Roche Major Business
2.2.3 Hoffmann-La Roche Bio-Therapeutic Glycoproteins Product and Services
2.2.4 Hoffmann-La Roche Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Hoffmann-La Roche Recent Developments/Updates
2.3 Genzyme Corp
2.3.1 Genzyme Corp Details
2.3.2 Genzyme Corp Major Business
2.3.3 Genzyme Corp Bio-Therapeutic Glycoproteins Product and Services
2.3.4 Genzyme Corp Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Genzyme Corp Recent Developments/Updates
2.4 Abbott Laboratories
2.4.1 Abbott Laboratories Details
2.4.2 Abbott Laboratories Major Business
2.4.3 Abbott Laboratories Bio-Therapeutic Glycoproteins Product and Services
2.4.4 Abbott Laboratories Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Abbott Laboratories Recent Developments/Updates
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business
2.5.3 Amgen Bio-Therapeutic Glycoproteins Product and Services
2.5.4 Amgen Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Amgen Recent Developments/Updates
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Bio-Therapeutic Glycoproteins Product and Services
2.6.4 Biogen Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Biogen Recent Developments/Updates
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Bio-Therapeutic Glycoproteins Product and Services
2.7.4 Merck Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Merck Recent Developments/Updates
2.8 GlaxoSmithKline
2.8.1 GlaxoSmithKline Details
2.8.2 GlaxoSmithKline Major Business
2.8.3 GlaxoSmithKline Bio-Therapeutic Glycoproteins Product and Services
2.8.4 GlaxoSmithKline Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 GlaxoSmithKline Recent Developments/Updates
2.9 Novartis Pharmaceuticals Corp
2.9.1 Novartis Pharmaceuticals Corp Details
2.9.2 Novartis Pharmaceuticals Corp Major Business
2.9.3 Novartis Pharmaceuticals Corp Bio-Therapeutic Glycoproteins Product and Services
2.9.4 Novartis Pharmaceuticals Corp Bio-Therapeutic Glycoproteins Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Novartis Pharmaceuticals Corp Recent Developments/Updates
3 Competitive Environment: Bio-Therapeutic Glycoproteins by Manufacturer
3.1 Global Bio-Therapeutic Glycoproteins Sales Quantity by Manufacturer (2019-2024)
3.2 Global Bio-Therapeutic Glycoproteins Revenue by Manufacturer (2019-2024)
3.3 Global Bio-Therapeutic Glycoproteins Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Bio-Therapeutic Glycoproteins by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Bio-Therapeutic Glycoproteins Manufacturer Market Share in 2023
3.4.2 Top 6 Bio-Therapeutic Glycoproteins Manufacturer Market Share in 2023
3.5 Bio-Therapeutic Glycoproteins Market: Overall Company Footprint Analysis
3.5.1 Bio-Therapeutic Glycoproteins Market: Region Footprint
3.5.2 Bio-Therapeutic Glycoproteins Market: Company Product Type Footprint
3.5.3 Bio-Therapeutic Glycoproteins Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bio-Therapeutic Glycoproteins Market Size by Region
4.1.1 Global Bio-Therapeutic Glycoproteins Sales Quantity by Region (2019-2030)
4.1.2 Global Bio-Therapeutic Glycoproteins Consumption Value by Region (2019-2030)
4.1.3 Global Bio-Therapeutic Glycoproteins Average Price by Region (2019-2030)
4.2 North America Bio-Therapeutic Glycoproteins Consumption Value (2019-2030)
4.3 Europe Bio-Therapeutic Glycoproteins Consumption Value (2019-2030)
4.4 Asia-Pacific Bio-Therapeutic Glycoproteins Consumption Value (2019-2030)
4.5 South America Bio-Therapeutic Glycoproteins Consumption Value (2019-2030)
4.6 Middle East and Africa Bio-Therapeutic Glycoproteins Consumption Value (2019-2030)
5 Market Segment by Type
5.1 Global Bio-Therapeutic Glycoproteins Sales Quantity by Type (2019-2030)
5.2 Global Bio-Therapeutic Glycoproteins Consumption Value by Type (2019-2030)
5.3 Global Bio-Therapeutic Glycoproteins Average Price by Type (2019-2030)
6 Market Segment by Application
6.1 Global Bio-Therapeutic Glycoproteins Sales Quantity by Application (2019-2030)
6.2 Global Bio-Therapeutic Glycoproteins Consumption Value by Application (2019-2030)
6.3 Global Bio-Therapeutic Glycoproteins Average Price by Application (2019-2030)
7 North America
7.1 North America Bio-Therapeutic Glycoproteins Sales Quantity by Type (2019-2030)
7.2 North America Bio-Therapeutic Glycoproteins Sales Quantity by Application (2019-2030)
7.3 North America Bio-Therapeutic Glycoproteins Market Size by Country
7.3.1 North America Bio-Therapeutic Glycoproteins Sales Quantity by Country (2019-2030)
7.3.2 North America Bio-Therapeutic Glycoproteins Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 Europe
8.1 Europe Bio-Therapeutic Glycoproteins Sales Quantity by Type (2019-2030)
8.2 Europe Bio-Therapeutic Glycoproteins Sales Quantity by Application (2019-2030)
8.3 Europe Bio-Therapeutic Glycoproteins Market Size by Country
8.3.1 Europe Bio-Therapeutic Glycoproteins Sales Quantity by Country (2019-2030)
8.3.2 Europe Bio-Therapeutic Glycoproteins Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific Bio-Therapeutic Glycoproteins Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Bio-Therapeutic Glycoproteins Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Bio-Therapeutic Glycoproteins Market Size by Region
9.3.1 Asia-Pacific Bio-Therapeutic Glycoproteins Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Bio-Therapeutic Glycoproteins Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 South America
10.1 South America Bio-Therapeutic Glycoproteins Sales Quantity by Type (2019-2030)
10.2 South America Bio-Therapeutic Glycoproteins Sales Quantity by Application (2019-2030)
10.3 South America Bio-Therapeutic Glycoproteins Market Size by Country
10.3.1 South America Bio-Therapeutic Glycoproteins Sales Quantity by Country (2019-2030)
10.3.2 South America Bio-Therapeutic Glycoproteins Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa Bio-Therapeutic Glycoproteins Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Bio-Therapeutic Glycoproteins Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Bio-Therapeutic Glycoproteins Market Size by Country
11.3.1 Middle East & Africa Bio-Therapeutic Glycoproteins Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Bio-Therapeutic Glycoproteins Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 Market Dynamics
12.1 Bio-Therapeutic Glycoproteins Market Drivers
12.2 Bio-Therapeutic Glycoproteins Market Restraints
12.3 Bio-Therapeutic Glycoproteins Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Bio-Therapeutic Glycoproteins and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bio-Therapeutic Glycoproteins
13.3 Bio-Therapeutic Glycoproteins Production Process
13.4 Bio-Therapeutic Glycoproteins Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bio-Therapeutic Glycoproteins Typical Distributors
14.3 Bio-Therapeutic Glycoproteins Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Genentech
Hoffmann-La Roche
Genzyme Corp
Abbott Laboratories
Amgen
Biogen
Merck
GlaxoSmithKline
Novartis Pharmaceuticals Corp
听
听
*If Applicable.
